Effect of cisapride on excessive regurgitation in infants

Clin Ther. 1989 Sep-Oct;11(5):669-77.


The relevance of the upper gastrointestinal motility-stimulating effects of cisapride for the treatment of excessive regurgitation and vomiting in infants was studied in 137 patients aged less than 1 year. They were treated with placebo or with cisapride, 0.1 to 0.2 mg/kg three times daily, for up to four weeks. In a dose-dependent fashion, cisapride significantly reduced the frequency and severity of regurgitation: after four weeks of treatment at 0.15 to 0.2 mg/kg, only about 20% of infants still had moderate or severe regurgitation, compared with about two thirds of those treated with placebo. Although only a few patients were followed up, the duration of treatment (four weeks) appeared to be long enough to minimize relapse. Side effects were limited to phenomena indicative of stimulated bowel motility.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial

MeSH terms

  • Cisapride
  • Dose-Response Relationship, Drug
  • Female
  • Gastroesophageal Reflux / drug therapy*
  • Humans
  • Infant
  • Infant, Newborn
  • Male
  • Piperidines / administration & dosage
  • Piperidines / adverse effects
  • Piperidines / therapeutic use*
  • Serotonin Antagonists / administration & dosage
  • Serotonin Antagonists / adverse effects
  • Serotonin Antagonists / therapeutic use*


  • Piperidines
  • Serotonin Antagonists
  • Cisapride